Misonix Announces New Distribution Agreement For Poland
FARMINGDALE, N.Y., May 24, 2012 /PRNewswire/ — Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications has entered into a new, three year, exclusive distribution agreement with WA-Med, based in Swidnik, Poland, for the distribution of the BoneScalpel(TM) Ultrasonic Bone Cutting System. The agreement provides WA-Med with the right to sell throughout Poland. Included in the agreement are annual minimum purchase requirements. Product training is in process and open market sales will commence shortly.
WA-Med, known for their market presence in spine and other orthopedic surgeries, is well prepared and well positioned to successfully introduce high tech products to the Polish market. Their commitment to product support and education is well known and separates them from the competition.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.
“We are pleased to add WA-Med to our developing distribution organization in Eastern Europe; their presence in a large, emerging market could add measurably to our sales success. We believe that partnering in new markets with organizations committed to customer service and education provides Misonix a competitive edge in developing relationships with the appropriate thought leaders that can, in turn, influence the medical community in their geographic areas to give our products a meaningful chance to attract their business. We think this is a “win/win” situation for all parties involved,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contacts Misonix Contact: Lytham Partners, LLC Richard Zaremba Robert Blum, Joe Dorame, Joe Diaz 631-694-9555 602-889-9700 email@example.com firstname.lastname@example.org
SOURCE Misonix, Inc.